Búsqueda | Portal de Búsqueda de la BVS España

1.

Everolimus.

Hasskarl, Jens.

Recent Results Cancer Res; 211: 101-123, 2018.

Artículo en Inglés | MEDLINE | ID: mdl-30069763

2.

ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes.

May, Annette M; Frey, Anna-Verena; Bogatyreva, Lioudmila; Benkisser-Petersen, Marco; Hauschke, Dieter; Lübbert, Michael; Wäsch, Ralph; Werner, Martin; Hasskarl, Jens; Lassmann, Silke.

Histochem Cell Biol; 141(4): 431-40, 2014 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-24292846

3.

Sorafenib: targeting multiple tyrosine kinases in cancer.

Hasskarl, Jens.

Recent Results Cancer Res; 201: 145-64, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-24756790

4.

Everolimus.

Hasskarl, Jens.

Recent Results Cancer Res; 201: 373-92, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-24756805

5.

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.

Van Le, Hoa; Van Naarden Braun, Kim; Nowakowski, Grzegorz S; Sermer, David; Radford, John; Townsend, William; Ghesquieres, Herve; Menne, Tobias; Porpaczy, Edit; Fox, Christopher P; Schusterbauer, Claudia; Liu, Fei Fei; Yue, Lihua; De Benedetti, Marc; Hasskarl, Jens.

Leuk Lymphoma; 64(3): 573-585, 2023 03.

Artículo en Inglés | MEDLINE | ID: mdl-36755418

6.

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.

Cartron, Guillaume; Fox, Christopher P; Liu, Fei Fei; Kostic, Ana; Hasskarl, Jens; Li, Daniel; Bonner, Ashley; Zhang, Yixie; Maloney, David G; Kuruvilla, John.

Exp Hematol Oncol; 11(1): 17, 2022 Mar 25.

Artículo en Inglés | MEDLINE | ID: mdl-35337365

7.

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Makita, Shinichi; Yamamoto, Go; Maruyama, Dai; Asano-Mori, Yuki; Kaji, Daisuke; Ananthakrishnan, Revathi; Ogasawara, Ken; Stepan, Lara; Schusterbauer, Claudia; Rettby, Nils; Hasskarl, Jens; Izutsu, Koji.

Cancer Med; 11(24): 4889-4899, 2022 12.

Artículo en Inglés | MEDLINE | ID: mdl-35619325

8.

Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.

Hasskarl, Jens; Kaufmann, Martina; Schmid, Herbert A.

Future Oncol; 7(7): 895-913, 2011 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-21732759

9.

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.

Salles, Gilles; Spin, Paul; Liu, Fei Fei; Garcia, Jacob; Kim, Yeonhee; Hasskarl, Jens.

Adv Ther; 38(6): 3266-3280, 2021 06.

Artículo en Inglés | MEDLINE | ID: mdl-33970454

10.

Elevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells.

Manthey, Carolin; Mern, Demissew S; Gutmann, Anja; Zielinski, Anne J; Herz, Corinna; Lassmann, Silke; Hasskarl, Jens.

BMC Cell Biol; 11: 2, 2010 Jan 14.

Artículo en Inglés | MEDLINE | ID: mdl-20070914

11.

Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells.

Mern, Demissew S; Hoppe-Seyler, Karin; Hoppe-Seyler, Felix; Hasskarl, Jens; Burwinkel, Barbara.

Breast Cancer Res Treat; 124(3): 623-33, 2010 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-20191379

12.

Sorafenib.

Hasskarl, Jens.

Recent Results Cancer Res; 184: 61-70, 2010.

Artículo en Inglés | MEDLINE | ID: mdl-20072831

13.

Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.

Schnitzler, Marc; Hasskarl, Jens; Egger, Matthias; Bertz, Hartmut; Finke, Jürgen.

Biol Blood Marrow Transplant; 15(8): 910-8, 2009 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-19589480

14.

Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability.

Piboonniyom, Siribang-on; Duensing, Stefan; Swilling, Nathan W; Hasskarl, Jens; Hinds, Philip W; Münger, Karl.

Cancer Res; 63(2): 476-83, 2003 Jan 15.

Artículo en Inglés | MEDLINE | ID: mdl-12543805

15.

The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers.

Hasskarl, Jens; Duensing, Stefan; Manuel, Edwin; Münger, Karl.

Oncogene; 23(10): 1930-8, 2004 Mar 11.

Artículo en Inglés | MEDLINE | ID: mdl-14755252

16.

Id proteins--tumor markers or oncogenes?

Hasskarl, Jens; Münger, Karl.

Cancer Biol Ther; 1(2): 91-6, 2002.

Artículo en Inglés | MEDLINE | ID: mdl-12170780

17.

Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.

Harder, Jan; Müller, Michael J; Fuchs, Matthias; Gumpp, Vera; Schmitt-Graeff, Annette; Fischer, Richard; Frank, Melanie; Opitz, Oliver; Hasskarl, Jens.

World J Gastroenterol; 19(48): 9334-42, 2013 Dec 28.

Artículo en Inglés | MEDLINE | ID: mdl-24409060

18.

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

Dietrich, Hartmut; Hu, Ke; Ruffin, Matthieu; Song, Dongweon; Bouillaud, Emmanuel; Wang, Yanfeng; Hasskarl, Jens.

Eur J Endocrinol; 166(5): 821-8, 2012 May.

Artículo en Inglés | MEDLINE | ID: mdl-22383336

19.

Increased in vitro lifespan of primary human keratinocytes correlates with decreased migration.

Hasskarl, Jens; Velupillai, Palanivel; Münger, Karl.

J Invest Dermatol; 126(5): 1179-81, 2006 May.

Artículo en Inglés | MEDLINE | ID: mdl-16484984

20.

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma.

Hasskarl, Jens; Ihorst, Gabriele; De Pasquale, David; Schröttner, Percy; Zerweck, Alf; Wäsch, Ralph; Engelhardt, Monika.

Leuk Lymphoma; 52(2): 247-59, 2011 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-21054148

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Everolimus.

ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes.

Sorafenib: targeting multiple tyrosine kinases in cancer.

Everolimus.

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.

Elevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells.

Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells.

Sorafenib.

Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.

Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability.

The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers.

Id proteins--tumor markers or oncogenes?

Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

Increased in vitro lifespan of primary human keratinocytes correlates with decreased migration.

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma.